However, the combination of CDK4/6 inhibitor and endocrine therapy significantly enhances the prognosis of patients with HER2-low breast cancer.19 These findings suggest that further investigation is warranted to explore the prognostic implications of HER2-low status and the intrinsic molecular characteristics of HER2-low breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.